Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.37 USD | -0.66% | -1.58% | +4.42% |
Apr. 23 | Edwards Lifesciences Corporation: The story continues | |
Apr. 15 | Exact Sciences Names Aaron Bloomer CFO | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in debt and has limited leeway for investment
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.42% | 20.56B | C+ | ||
-3.72% | 184B | C+ | ||
-2.60% | 107B | C | ||
-3.79% | 67.78B | A | ||
+2.66% | 50.66B | B- | ||
+16.39% | 47.64B | B- | ||
+4.60% | 41.12B | B+ | ||
+1.38% | 26.3B | B | ||
+1.52% | 26.04B | A- | ||
-1.17% | 24.71B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BAX Stock
- Ratings Baxter International Inc.